1. Scrip
  2. >>Therapy Areas

Novartis Drug Discovery Centralization Brings R&D Relocations, Job Cuts

 
• By Sten Stovall

Novartis' efforts to rationalize and centralize its drug discovery programs will see the Novartis Institute for Tropical Diseases moved from Singapore to California and the closure of biologics units in Shanghai and in the Swiss town of Schlieren.

Creation by Novartis AG of a unified early discovery research group based both in Basel, Switzerland and Cambridge, MA USA - aimed at centralizing control over drug discovery and curb costs - is prompting the relocation of its research base for tropical diseases from Singapore to Emeryville, Cali. and the closure of its biologics divisions in Shanghai, China and Schlieren, Switzerland.

The changes are part of Novartis' decision to re-organize drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.